Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68446 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8621066 | 0.78 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7139454 | 0.77 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL16586266 | 0.77 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29396065 | 0.77 | HCAR2 (0.53) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL24616691 | 0.77 | HCAR2 (0.53) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15304743 | 0.77 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL9081038 | 0.77 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15981181 | 0.77 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.77 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.